CD15 Flow Cytometry: Reading a Glycan Antigen on Myeloid Cells and Tumour Tissue
Most flow cytometry targets are proteins encoded by a gene. CD15 is not. It is a fucosylated carbohydrate. That single fact changes how the reagent behaves and how the signal varies between cells. It also explains why a panel built for protein markers often underperforms on CD15. This guide works through the molecular biology, the two clinical settings where the marker is most useful, and the conjugate choices that follow.
A Marker Defined by Its Sugar, Not Its Gene
CD15 is also known as Lewis X antigen or SSEA-1. Its chemical identity is 3-fucosyl-N-acetyllactosamine. No gene encodes it directly. Instead, it is a post-translational glycosylation product added to certain surface proteins, and it appears on cells from kidney, prostate, bladder, acute leukaemia, hepatocellular carcinoma, breast and melanoma.
That biosynthetic route has a practical consequence. Expression is governed by the glycosylation machinery of the cell, not by a promoter. Two cells with identical surface protein levels can differ in CD15 signal if their fucosylation pathways differ. The source literature makes this point explicitly: expression varies considerably between cell types and between differentiation stages. A panel should therefore treat CD15 intensity as a modulated feature rather than a fixed one.
Four-panel infographic showing the molecular nature of CD15 as 3-fucosyl-N-acetyllactosamine, its expression on surface proteins across cancer types, its functional roles and its selectin-dependent metastatic mechanism
What the Molecule Does
CD15 participates in cell adhesion, migration, chemotaxis, immune recognition and phagocytosis. Its adhesion function runs through the selectins. CD15 engages E-selectin, L-selectin and P-selectin, which allows cancer cells to attach to endothelial cells and may promote metastasis.
The mechanism resembles the rolling and adhesion sequence that leukocytes use at sites of inflammation. The implication is uncomfortable but well supported: tumour cells appear to have hijacked a normal trafficking system. CD15 is therefore not merely a label on malignant cells. It may be a functional participant in their spread.
The Hodgkin Lymphoma Pair
CD15 labels Reed-Sternberg cells well and is a key marker in Hodgkin lymphoma. In diagnostic practice it is used together with CD30. The classic immunophenotype is CD15 positive and CD30 positive.
The molecular logic is straightforward. Reed-Sternberg cells abnormally express the CD15 carbohydrate antigen, while normal lymphocytes express little or none. Flow cytometry and immunohistochemistry can therefore help separate Hodgkin lymphoma from other lymphoma types. CD15 also marks neoplastic Reed-Sternberg cells specifically, which reinforces its diagnostic role.
One further observation is worth keeping in mind. CD15 is expressed on immature cells, including a range of central nervous system progenitors, and it is important in fetal central nervous system development. Reactivity in neural or progenitor contexts should therefore be interpreted with that biology in view rather than treated as artefact.
Solid Tumour Prognosis
In gastric, colorectal, thyroid and breast cancer, CD15 expression rises as differentiation falls, nodal metastasis appears and clinical stage advances. Expression is consequently a usable indicator of tumour progression, nodal involvement and prognosis.
Two mechanisms plausibly connect the marker to outcome. CD15-mediated adhesion promotes binding of tumour cells to vascular endothelium, which supports metastatic potential. Separately, upregulated expression accompanies loss of differentiation, which places CD15 inside the dedifferentiation programme rather than beside it. On that reading, the marker is both a readout and a contributor.
The Myeloid Compartment
In immune settings CD15 is a myeloid antigen, present in the myeloid and monocyte lineages. It participates in neutrophil functions, including cell-to-cell interaction and adhesion to endothelium. It mediates neutrophil adhesion to dendritic cells and serves as a granulocyte marker.
In flow cytometry, CD15 is used routinely to identify neutrophils and myeloid cells. Combined with CD16 and CD11b it resolves myeloid subsets with reasonable precision. Expression also carries prognostic information in some settings, and the molecule has been discussed as a monoclonal antibody therapeutic target.
Matching Conjugate to Readout
| Cat. No. | Product Name | Typical readout | Purchase |
|---|---|---|---|
| S0B1264 | Mouse Anti-Human CD15 Antibody (HI98) | Secondary detection, staining, custom labelling | |
| S0B8709 | FITC Mouse Anti-Human CD15 Antibody (HI98) | Conventional blue-laser panel, bright population | |
| S0B5423 | Biotin Mouse Anti-Human CD15 Antibody (HI98) | Amplification with streptavidin reagents | |
| S0B5955 | Alexa Fluor® 488 Mouse Anti-Human CD15 Antibody (HI98) | Brighter alternative in the 488 channel |
All four reagents share the HI98 clone, which means the epitope is constant and only the detection chemistry changes. That is useful for panel development, because a signal difference between two tubes can be attributed to the conjugate rather than to a different binder.
Where CD15 Fits, and Where It Does Not
CD15 answers lineage and differentiation questions well. It does not answer abundance questions well, because the signal depends on glycosylation state rather than on a fixed number of epitopes per cell. A dim population may be low expressers or poorly fucosylated cells, and the two carry different meanings.
The marker is also weak as a single-parameter diagnostic. Its value in Hodgkin lymphoma comes from the CD15 and CD30 combination, and its value in myeloid work comes from pairing with CD16 and CD11b. Used alone, it produces ambiguous results that invite overinterpretation. Used inside a defined panel, it contributes information that no protein marker duplicates, because the glycan reflects a metabolic pathway rather than a transcript.
Reading the Panel
Three practical points follow from the glycan biology. First, intensity calibration should be repeated when the cell system changes, because glycosylation differs between lines and between primary preparations. Second, an unconjugated format is the right starting point when the epitope itself is under investigation, since it separates binding from label effects. Third, the biotin format is the choice when the target population is dim, because streptavidin amplification recovers signal that a direct conjugate loses.
For myeloid panels, CD15 belongs with CD16 and CD11b rather than standing alone. For lymphoma work, it belongs beside CD30. In both cases the marker answers a question about lineage or differentiation, and the answer is only as good as the panel around it. Reagents described here are supplied for research use only.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.
